These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3090927)

  • 1. Quantitation of intercellular binding strength by disruptive centrifugation: application to the analysis of adhesive interactions between P815 tumour cells and activated macrophages.
    Lepoivre M; Lemaire G
    Ann Inst Pasteur Immunol (1985); 1986; 137C(3):329-44. PubMed ID: 3090927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High strength binding of P815 mastocytoma cells is not necessary for their lysis by macrophages which have been primed and triggered in vitro.
    Lu CY; Lombardi MJ; Shea CM; Dustin LB
    J Immunol; 1988 Aug; 141(4):1083-90. PubMed ID: 3135320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of the strength of cell-cell adhesion: the capture of tumor cells by activated murine macrophages proceeds through two distinct stages.
    Somers SD; Whisnant CC; Adams DO
    J Immunol; 1986 Feb; 136(4):1490-6. PubMed ID: 3080524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-gamma differentially modulates the susceptibility of L1210 and P815 tumor targets for macrophage-mediated cytotoxicity. Role of macrophage-target interaction coupled to nitric oxide generation, but independent of tumor necrosis factor production.
    Leu RW; Leu NR; Shannon BJ; Fast DJ
    J Immunol; 1991 Sep; 147(6):1816-22. PubMed ID: 1909732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of activated macrophages with normal and neoplastic cells.
    La Posta VJ; Kotlarski I
    Aust J Exp Biol Med Sci; 1982 Oct; 60 (Pt 5)():513-28. PubMed ID: 6819844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine macrophage cytotoxicity induced by mastocytoma cells, cell-free mastocytoma exudates, and extracts.
    Dullens HF; Den Otter W
    Immunopharmacology; 1981 Sep; 3(3):241-51. PubMed ID: 6796544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences.
    Kamate C; Baloul S; Grootenboer S; Pessis E; Chevrot A; Tulliez M; Marchiol C; Viguier M; Fradelizi D
    Int J Cancer; 2002 Aug; 100(5):571-9. PubMed ID: 12124807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecular weight peptide from P815 mastocytoma cells induces macrophage cytotoxicity.
    Dullens HF; den Otter W
    Immunopharmacology; 1981 Dec; 3(4):309-16. PubMed ID: 6799426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of assay medium composition on macrophage-mediated tumor cell binding and lysis.
    Hasday JD; Crawford EK
    J Immunol Methods; 1988 Nov; 114(1-2):243-52. PubMed ID: 3141516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast cell granules inhibit macrophage-mediated lysis of mastocytoma cells (P815) and nitric oxide production.
    Dileepan KN; Lorsbach RB; Stechschulte DJ
    J Leukoc Biol; 1993 Apr; 53(4):446-53. PubMed ID: 8482925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of macrophage binding to virally infected cells by low levels of lipopolysaccharide.
    Derrick SC; LeBlanc PA
    J Leukoc Biol; 1995 Apr; 57(4):569-73. PubMed ID: 7722416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activity of lymphokine-activated macrophages in host defense against neoplasia.
    Fernandez-Cruz E; Ulich T; Schreiber RD
    J Immunol; 1985 May; 134(5):3489-96. PubMed ID: 3920323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tumor cell capture by activated macrophages: evidence for involvement of lymphocyte function-associated (LFA)-1 antigen.
    Strassmann G; Springer TA; Somers SD; Adams DO
    J Immunol; 1986 Jun; 136(11):4328-33. PubMed ID: 2422281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo macrophage-mediated tumor cytotoxicity in the mouse.
    Cameron DJ
    Immunol Lett; 1982 Jun; 4(6):321-5. PubMed ID: 6811424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-dependent cytolysis (ADCC) of tumor cells by activated murine macrophages is a two-step process: quantification of target binding and subsequent target lysis.
    Johnson WJ; Bolognesi DP; Adams DO
    Cell Immunol; 1984 Jan; 83(1):170-80. PubMed ID: 6420078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of P815: a warning.
    Dullens HF; Den Otter W
    Immunol Lett; 1983 Jun; 6(6):309-10. PubMed ID: 6414945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of suppressor cells in mice bearing syngeneic mastocytoma.
    Takei F; Levy JG; Kilburn DG
    J Immunol; 1977 Feb; 118(2):412-7. PubMed ID: 65423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
    Carayanniotis G; Halloran PF
    Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retroviral peptide encoded by mutated env p15E gene is recognized by specific CD8+ T lymphocytes on drug-treated murine mastocytoma P815.
    Belladonna ML; Fioretti MC; Bianchi R; Puccetti P; Grohmann U
    Int J Immunopharmacol; 1996 Oct; 18(10):563-76. PubMed ID: 9080250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific reversal of cytolytic T cell-target cell functional binding is induced by free target cells.
    Balk SP; Mescher MF
    J Immunol; 1981 Jul; 127(1):51-7. PubMed ID: 6787131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.